Stay updated on Pembrolizumab Combo in Ovary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovary Cancer Clinical Trial page
- Check2 days agoChange DetectedThe site footer revision identifier was updated from v3.8.0 to v3.8.1, with no change to the clinical trial record content.SummaryDifference0.0%

- Check9 days agoChange DetectedThe clinical trial page now displays the study record for a Phase II pembrolizumab, carboplatin, and paclitaxel trial for epithelial ovarian cancer, including its completed status, study design, eligibility criteria, and outcome measures.SummaryDifference62%

- Check16 days agoChange DetectedThe footer’s displayed ClinicalTrials.gov revision changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedA site-wide NIH notice about the terminology transition from “AI” to “SI” appears above the page, which still displays a 403 error. The footer revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1 on the 403 Forbidden page; no study details are shown.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study page now loads a 403 Forbidden error instead of displaying the trial details, indicating the record is currently inaccessible. The error page is shown with the standard site chrome and a 403 message, preventing access to the study information.SummaryDifference20%

Stay in the know with updates to Pembrolizumab Combo in Ovary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.